Following the success of the first multi-stakeholder workshop to accelerate the development of treatments for patients with RDH12-associated inherited retinal dystrophies in 2019, the patient organizations Eyes on the Future and the RDH12 Fund for Sight convened a second one day, multi-stakeholder workshop in November 2022, focusing on the challenges in clinical trial design and outcome measure selection for studies involving patients with RDH12-associated inherited retinal disease (IRD). The gene discussed is RDH12; the disease is inherited retinal dystrophy.